• Explore /
  • Poster
  • / Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

Abstract Poster

Authors

null

Audreylie Lemelin

Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

Audreylie Lemelin , Matthew Scott Ernst , Connor Wells , Vishal Navani , Bradley Alexander McGregor , Shirley S. Wong , Sumanta Monty Pal , Naveen S. Basappa , Anil Kapoor , Jae-Lyun Lee , Frede Donskov , Haoran Li , Takeshi Yuasa , Rose Chang , Lynn Huynh , Catherine Nguyen , Ashley Holub , Louise Clear , Mei Sheng Duh , Daniel Yick Chin Heng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 673)

DOI

10.1200/JCO.2023.41.6_suppl.673

Abstract #

673

Poster Bd #

H5

Abstract Disclosures

Similar Posters

First Author: Joseph Vento

First Author: Chun Loo Gan

First Author: Daniel M. Geynisman

First Author: Shaan Dudani